129 related articles for article (PubMed ID: 38346438)
21. One-sample quantitative and two-sample qualitative faecal immunochemical tests for colorectal cancer screening: a cross-sectional study in China.
Wang L; Chen H; Zhu Y; Lu M; Wang Y; Chen X; Ma W; Du L; Chen W
BMJ Open; 2022 May; 12(5):e059754. PubMed ID: 35589365
[TBL] [Abstract][Full Text] [Related]
22. Fecal Immunologic Test Results and Diagnostic Colonoscopy in a Mexican Population at Average Risk for Colorectal Cancer.
Manzano-Robleda MDC; Espinosa-Tamez P; Potter MB; Lajous M; Van Loon K; Zhang L; Jimenez-Peña A; Sánchez Del Monte J; Mohar A; Hernández-Guerrero A
Cancer Prev Res (Phila); 2020 Nov; 13(11):959-966. PubMed ID: 32655008
[TBL] [Abstract][Full Text] [Related]
23. Long-Term Impact of the Dutch Colorectal Cancer Screening Program on Cancer Incidence and Mortality-Model-Based Exploration of the Serrated Pathway.
Greuter MJ; Demirel E; Lew JB; Berkhof J; Xu XM; Canfell K; Dekker E; Meijer GA; Coupé VM
Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):135-44. PubMed ID: 26598535
[TBL] [Abstract][Full Text] [Related]
24. Fresh vs Frozen Samples and Ambient Temperature Have Little Effect on Detection of Colorectal Cancer or Adenomas by a Fecal Immunochemical Test in a Colorectal Cancer Screening Cohort in Germany.
Chen H; Werner S; Brenner H
Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1547-1556.e5. PubMed ID: 27793749
[TBL] [Abstract][Full Text] [Related]
25. Detection rate and predictive factors of sessile serrated polyps in an organised colorectal cancer screening programme with immunochemical faecal occult blood test: the EQuIPE study (Evaluating Quality Indicators of the Performance of Endoscopy).
Zorzi M; Senore C; Da Re F; Barca A; Bonelli LA; Cannizzaro R; de Pretis G; Di Furia L; Di Giulio E; Mantellini P; Naldoni C; Sassatelli R; Rex DK; Zappa M; Hassan C;
Gut; 2017 Jul; 66(7):1233-1240. PubMed ID: 26896459
[TBL] [Abstract][Full Text] [Related]
26. Impact of differences in adenoma and proximal serrated polyp detection rate on the long-term effectiveness of FIT-based colorectal cancer screening.
Bronzwaer MES; Greuter MJE; Bleijenberg AGC; IJspeert JEG; Dekker E; Coupé VMH
BMC Cancer; 2018 Apr; 18(1):465. PubMed ID: 29695244
[TBL] [Abstract][Full Text] [Related]
27. Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia.
Smith A; Young GP; Cole SR; Bampton P
Cancer; 2006 Nov; 107(9):2152-9. PubMed ID: 16998938
[TBL] [Abstract][Full Text] [Related]
28. Faecal immunochemical test after negative colonoscopy may reduce the risk of incident colorectal cancer in a population-based screening programme.
Peng SM; Hsu WF; Wang YW; Lin LJ; Yen AM; Chen LS; Lee YC; Wu MS; Chen TH; Chiu HM
Gut; 2021 Jul; 70(7):1318-1324. PubMed ID: 32989019
[TBL] [Abstract][Full Text] [Related]
29. Screening uptake of colonoscopy versus fecal immunochemical testing in first-degree relatives of patients with non-syndromic colorectal cancer: A multicenter, open-label, parallel-group, randomized trial (ParCoFit study).
González-López N; Quintero E; Gimeno-Garcia AZ; Bujanda L; Banales J; Cubiella J; Salve-Bouzo M; Herrero-Rivas JM; Cid-Delgado E; Alvarez-Sanchez V; Ledo-Rodríguez A; de-Castro-Parga ML; Fernández-Poceiro R; Sanromán-Álvarez L; Santiago-Garcia J; Herreros-de-Tejada A; Ocaña-Bombardo T; Balaguer F; Rodríguez-Soler M; Jover R; Ponce M; Alvarez-Urturi C; Bessa X; Roncales MP; Sopeña F; Lanas A; Nicolás-Pérez D; Adrián-de-Ganzo Z; Carrillo-Palau M; González-Dávila E;
PLoS Med; 2023 Oct; 20(10):e1004298. PubMed ID: 37874831
[TBL] [Abstract][Full Text] [Related]
30. Faecal haemoglobin concentration influences risk prediction of interval cancers resulting from inadequate colonoscopy quality: analysis of the Taiwanese Nationwide Colorectal Cancer Screening Program.
Chiu SY; Chuang SL; Chen SL; Yen AM; Fann JC; Chang DC; Lee YC; Wu MS; Chou CK; Hsu WF; Chiou ST; Chiu HM
Gut; 2017 Feb; 66(2):293-300. PubMed ID: 26515543
[TBL] [Abstract][Full Text] [Related]
31. Feasibility and economic assessment of chromocolonoscopy for detection of proximal serrated neoplasia within a population-based colorectal cancer screening programme (CONSCOP): an open-label, randomised controlled non-inferiority trial.
Hurt C; Ramaraj R; Farr A; Morgan M; Williams N; Philips CJ; Williams GT; Gardner G; Porter C; Sampson J; Hillier S; Heard H; Dolwani S;
Lancet Gastroenterol Hepatol; 2019 May; 4(5):364-375. PubMed ID: 30885505
[TBL] [Abstract][Full Text] [Related]
32. Screening for Colorectal Cancer With Fecal Immunochemical Testing With and Without Postpolypectomy Surveillance Colonoscopy: A Cost-Effectiveness Analysis.
Greuter MJE; de Klerk CM; Meijer GA; Dekker E; Coupé VMH
Ann Intern Med; 2017 Oct; 167(8):544-554. PubMed ID: 28973514
[TBL] [Abstract][Full Text] [Related]
33. Faecal haemoglobin concentration among subjects with negative FIT results is associated with the detection rate of neoplasia at subsequent rounds: a prospective study in the context of population based screening programmes in Italy.
Senore C; Zappa M; Campari C; Crotta S; Armaroli P; Arrigoni A; Cassoni P; Colla R; Fracchia M; Gili F; Grazzini G; Lolli R; Menozzi P; Orione L; Polizzi S; Rapi S; Riggi E; Rubeca T; Sassatelli R; Visioli C; Segnan N
Gut; 2020 Mar; 69(3):523-530. PubMed ID: 31455608
[TBL] [Abstract][Full Text] [Related]
34. Impact of screening and follow-up colonoscopy adenoma sensitivity on colorectal cancer screening outcomes in the CRC-AIM microsimulation model.
Fisher DA; Saoud L; Hassmiller Lich K; Fendrick AM; Ozbay AB; Borah BJ; Matney M; Parton M; Limburg PJ
Cancer Med; 2021 Apr; 10(8):2855-2864. PubMed ID: 33314646
[TBL] [Abstract][Full Text] [Related]
35. Adding family history to faecal immunochemical testing increases the detection of advanced neoplasia in a colorectal cancer screening programme.
Kallenberg FG; Vleugels JL; de Wijkerslooth TR; Stegeman I; Stoop EM; van Leerdam ME; Kuipers EJ; Bossuyt PM; Dekker E
Aliment Pharmacol Ther; 2016 Jul; 44(1):88-96. PubMed ID: 27170502
[TBL] [Abstract][Full Text] [Related]
36. Comparison of faecal M2-PK and FIT in a population-based bowel cancer screening cohort.
Leen R; Seng-Lee C; Holleran G; O'Morain C; McNamara D
Eur J Gastroenterol Hepatol; 2014 May; 26(5):514-8. PubMed ID: 24699725
[TBL] [Abstract][Full Text] [Related]
37. Colonoscopy Findings in FIT+ and mt-sDNA+ Patients versus in Colonoscopy-only Patients: New Hampshire Colonoscopy Registry Data.
Anderson JC; Robinson CM; Hisey W; Limburg PJ; Butterly LF
Cancer Prev Res (Phila); 2022 Jul; 15(7):455-464. PubMed ID: 35378546
[TBL] [Abstract][Full Text] [Related]
38. Multitarget Stool DNA Test Performance in an Average-Risk Colorectal Cancer Screening Population.
Bosch LJW; Melotte V; Mongera S; Daenen KLJ; Coupé VMH; van Turenhout ST; Stoop EM; de Wijkerslooth TR; Mulder CJJ; Rausch C; Kuipers EJ; Dekker E; Domanico MJ; Lidgard GP; Berger BM; van Engeland M; Carvalho B; Meijer GA
Am J Gastroenterol; 2019 Dec; 114(12):1909-1918. PubMed ID: 31764091
[TBL] [Abstract][Full Text] [Related]
39. One or two faecal immunochemical tests in an organised population-based colorectal cancer screening programme in Murcia (Spain).
Tourne-Garcia C; Perez-Riquelme F; Monteagudo-Piqueras O; Fraser CG; Yepes-Garcia P
J Med Screen; 2022 Dec; 29(4):231-240. PubMed ID: 35578555
[TBL] [Abstract][Full Text] [Related]
40. An analysis of the duplicate testing strategy of an Irish immunochemical faecal occult blood test colorectal cancer screening programme.
Kelley L; Swan N; Hughes DJ
Colorectal Dis; 2013 Sep; 15(9):e512-21. PubMed ID: 23746062
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
